SCM
CNTB

Silverarc Capital Management’s Connect Biopharma Holdings CNTB Stock Holding History

Silverarc Capital Management’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
+545,000
New +$1.32M 0.13% 68

Other funds holding CNTB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Silverarc Capital Management's CNTB Position: Q2 2026 in Review

Silverarc Capital Management opened a new position in Connect Biopharma Holdings (CNTB) in Q2 2026: 545,000 shares worth $1.3M. The stake represents 0.13% of the portfolio and ranks #68 among its holdings.

34 funds tracked by Wall St. Rank hold CNTB as of Q2 2026.

  • Silverarc Capital Management held 545,000 shares of Connect Biopharma Holdings worth $1.3M as of Q2 2026.
  • Connect Biopharma Holdings was a new Silverarc Capital Management position in Q2 2026.
  • Connect Biopharma Holdings made up 0.13% of Silverarc Capital Management's portfolio in Q2 2026, its #68 holding.
  • 34 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.